flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes Semaglutide in Patients with Obesity-Related
Description
Where Tirzepatide Still Looks Strong Tirzepatide is still excellent
William E
A user targeting 1 mg who accidentally draws 1.3 mg has a 30% overdose
What the titration schedule is specifically not designed to accommodate is rushing to the highest dose quickly
Tirzepatide as an alternative Some patients respond better to tirzepatide than semaglutide
